Atlas Trials

Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients

Clinical trial NCT02625935 · COMPLETED

Trial details

NCT number
NCT02625935
Sponsor
NanoString Technologies, Inc.
Status
COMPLETED
Study type
OBSERVATIONAL
Breast Cancer
Start date
2015-12-01
Primary completion
2017-06-01
Enrollment
206

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.